Handbook Of Hematologic Malignancies

Women diagnosed with hematological malignancies during pregnancy face higher severe maternal morbidity and obstetric complications compared to post-pregnancy diagnoses. The study analyzed data from ...

Patients with hematologic malignancies face significantly higher short- and long-term risk for cardiovascular disease vs the general public.

In this free webinar, gain insight into new changes in molecular reclassification of hematologic malignancies and their effects in precision medicine. Attendees will learn about the use of molecular ...

The American Journal of Managed Care: COVID-19 Risk Remains High for Patients With Hematologic Malignancies

Handbook Of Hematologic Malignancies 4

Hematologic malignancies most often present in the sixth or seventh decade of life. Even so, many older adults may be unable to tolerate standard chemotherapy or require supplementary care or dose ...

Patients with Sjögren disease (SjD) had a 68% higher risk for overall malignancy than the general population, with hematologic malignancies contributing more to this elevated risk than solid tumors.

Handbook Of Hematologic Malignancies 6

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and leukemia. CAR T-cell therapy is a unique way of treating hematologic ...

Labroots: Continuous Low-Dose Lenalidomide Delivery for Hematologic Malignancies: Preclinical to Phase 2 Insights

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

Handbook Of Hematologic Malignancies 9

Continuous Low-Dose Lenalidomide Delivery for Hematologic Malignancies: Preclinical to Phase 2 Insights

Table 1. Common causes and pathogenic mechanisms of acute and chronic renal impairment in patients with hematological malignancies. Category Causes and pathogenetic mechanisms Ref. Disease related ...

This chart illustrates the trends in ASIR and ASMR of major hematological malignancies, including HL, NHL, MM, and leukemia, across the world, China, and the United States from 1990 to 2021. Based on ...